Iranian-made Bovine Serum Albumin Nanoparticles as a Tamoxifen Tumor‐targeted Delivery System
Researchers at the Zanjan University of Medical Sciences has introduced cholesterol (CLO)‐conjugated bovine serum albumin nanoparticles (BSA NPs) as a new system for indirect targeting drug delivery.
Finding the required drug dosage is one of the biggest challenges in cancer therapy, achieving a desired amount of drug at the tumor site in an effective period. The other significant challenge in cancer therapy is finding an effective approach to distinguish between the cancerous cells and the healthy body cells.
The bovine serum albumin nanoparticles (BSA NPs) are one of the most attractive systems for drug delivery because it is readily available, nontoxic, non-immunogenic, biocompatible, and biodegradable. BSA is a commercially available protein, which has widely been used in drug delivery, Nano-carrier development, imaging, sensing, and self‐assembly.
In the aforementioned study, CLO‐BSA‐TAX nanoparticles were designed and synthesized. The physicochemical properties, toxicity, in vitro, and in vivo biocompatibility of the BSA nanoparticles system were characterized on cancer cell lines. Tamoxifen (TAX), as an anticancer drug, was loaded on these nanoparticles (BSA‐TAX NPs).
The CLO‐modified BSA nanoparticles system had more potential in suppressing tumors compared to the non-targeted BSA nanoparticles system. Hence, the CLO‐modified BSA NPs system is a promising drug targeting delivery system to tumor cells.
As a result, Iranian researchers reported a novel approach for targeting tumor cells, where CLO was used as an indirect targeting agent. It can be concluded from the paper that the CLO, as an indirect targeting agent, enhances the toxicity and specificity of NPs system on cancer cell lines. It could potentially be suitable approaches for targeting the tumors in clinical cancer therapy.